gms | German Medical Science

67. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Koreanischen Gesellschaft für Neurochirurgie (KNS)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

12. - 15. Juni 2016, Frankfurt am Main

Artikel

Artikel empfehlen

Gamma knife radiosurgery for residual or recurrent intracranial hemangiopericytomas

Meeting Abstract

Suche in Medline nach

  • Byung Sup Kim - Department of Neurosurgery, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • Doo-Sik Kong - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • Ho Jun Seol - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • Do-Hyun Nam - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • Jung-Il Lee - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Deutsche Gesellschaft für Neurochirurgie. 67. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 1. Joint Meeting mit der Koreanischen Gesellschaft für Neurochirurgie (KNS). Frankfurt am Main, 12.-15.06.2016. Düsseldorf: German Medical Science GMS Publishing House; 2016. DocP 075

doi: 10.3205/16dgnc450, urn:nbn:de:0183-16dgnc4505

Veröffentlicht: 8. Juni 2016

© 2016 Kim et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Objective: Residual or recurrent hemangiopericytoma (HPC) has been treated with radiosurgery; however, its long-term outcome is not well known.

Method: We conducted a retrospective analysis of 18 patients who underwent gamma knife radiosurgery (GKS) for residual or recurrent HPCs.

Results: Of the 18 patients, 10 patients had high-grade HPCs (27 tumors) and 8 had low-grade HPCs (13 tumors). Median overall survival (OS) after the first GKS was 134.7 months and actuarial survival rate at 1, 5, and 10 years was 94.4, 85.9, and 58.0%, respectively. At the last follow-up, intracranial tumor control was achieved in 12 (66.7%) of 18 patients. New lesions developed out of initial GKS target in 8 patients (44.4%). They were also treated with additional GKS and a total of 40 tumors were treated. The actuarial local control rate of 40 tumors at 1, 3, and 5 years was 89.0, 66.9, and 46.1%, respectively. The median local recurrence-free interval of 40 tumors after initial GKS for each lesion was 86.1 months for low-grade and 40.5 months for high-grade tumors (p = 0.004). Extracranial metastases developed in 7 (38.9%) patients with high-grade pathology and became a cause of death in 3 patients.

Conclusions: Intracranial tumor control can be achieved over the long term, though additional GKS is frequently necessary. Extracranial metastasis is common in HPC of high-grade pathology. Close surveillance and aggressive treatment is recommended not only for intracranial tumor but also for possible extracranial metastases.